Active Substance: Urofollitropin (FSH).
Overview
Welcome to Dwaey, specifically on FOSTIMON 75 IU page.
This medicine contains an important and useful components, as it consists of
Urofollitropin (FSH)is available in the market in concentration
Urofollitropin
May result in multiple pregnancies. Abnormal genital bleeding, hormone sensitive malignancies, ovarian cysts not caused by polycystic ovary syndrome. Exclude and treat other causes of infertility e.g. pituitary or hypothalamic lesions, adrenal or thyroid disorders and hyperprolactinaemia.
Female infertility, Hypogonadotrophic hypogonadism
Pregnancy, ovarian cysts or enlargement not due to polycystic ovary syndrome, primary ovarian failure, organic intracranial lesion e.g. pituitary tumour, uncontrolled thyroid and adrenal dysfunction, presence of any cause of infertility other than anovulation, abnormal bleeding of undetermined origin.
>10% Headache (11.1%), OHSS (11.1%; severe pelvic pain, N/V, weight gain) Frequency Not Defined Nausea, vomiting, joint pain, ovarian hyperstimulation syndrome, adnexal torsion, mild to moderate ovarian enlargement, abdominal pain, ovarian cysts, local reaction at inj site, headaches, haemoperitoneum, benign and malignant ovarian neoplasms, ascites, pleural effusion, hypovolaemia, thromboembolic disorders. Weight gain, acne and gynaecomastia in men. Potentially Fatal: Ovarian cysts rupture, intraperitoneal haemorrhage.
5
Urofollitropin, a gonadotrophin obtained from postmenopausal women's urine, possesses follicle-stimulating hormone (FSH) activity but almost no luteinising activity. Admin for 7-12 days results in follicular growth and maturation in females. When sufficient follicular maturation has occurred, human chorionic gonadotrophin should be given to induce ovulation.
Increased risk of ovarian hyperstimulation syndrome with drugs with luteinising hormone activity.
Information not available